Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)

This study tests a non-invasive treatment called amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) — a device that delivers painless low-level electromagnetic energy — combined with standard immunotherapy (anti-PD-L1 and anti-CTLA-4 drugs) for people with advanced liver cancer (hepatocellular carcinoma) who have not yet received systemic treatment. **You may be eligible if...** - You are 18 or older - You have been diagnosed with hepatocellular carcinoma (liver cancer) confirmed by biopsy - Your cancer cannot be removed by surgery or treated by local procedures - You have not yet received any systemic (drug) therapy for liver cancer - Your liver function is still reasonably good (Child-Pugh score B7 or better) - You have measurable disease on imaging **You may NOT be eligible if...** - You have received prior systemic therapy for liver cancer - Your liver function is severely impaired - You are pregnant or breastfeeding - Your ECOG performance status is above 2 (meaning significant disability) Talk to your doctor to see if this trial is right for you.